Table 1

Baseline clinical characteristics of the study patients in both groups

Half-dose rt-PA (n=38)LMWH (n=38)P value
Age69±1463±160.085
Sex, n (%)0.107
 Male21 (55)14 (37)
 Female17 (45)24 (64)
SBP (mm Hg)126±23124±170.9
DBP (mm Hg)77±1380±110.758
Respiratory rate (per minute)26±2.924±3.20.006
 Oxygen saturation (in room air)88±4.891±4.80.019
PaO2 (mm Hg)62±5.870±6.20.032
Troponin (g/mL)2.60±0.42.48±0.40.685
Risk factors, n (%)
Immobility27 (71)22 (60)0.338
Malignancy8 (21)7 (18)1.000
DVT history6 (16)9 (24)0.564
PE history4 (10)3 (8)1.000
Obesity (BMI >30 kg/m²)10 (26)15 (40)0.329
Surgery (in the last 45 days)8 (21)10 (26)0.787
Trauma (in the last 45 days)3 (8)2 (5)1.000
Hormone therapy1 (3)4 (10)0.358
Presenting symptoms, n (%)
Dyspnea37 (97)36 (94)1.000
Chest pain22 (60)26 (68)0.476
Cough3 (8)6 (16)0.480
Hemoptysis3 (8)3 (8)1.000
Syncope1 (3)0 (0)1
Duration of illness (days)1.601.860.07
  • BMI, body mass index; DBP, diastolic blood pressure; DVT, deep venous thrombosis; LMWH, low molecular weight heparin; PaO2, partial pressure of arterial oxygen; rt-PA, tissue-type plasminogen activator; SBP, systolic blood pressure.